CARGO Therapeutics, Inc. (CRGX)
After hours:
| Previous Close | 20.38 |
| Open | 19.51 |
| Bid | 18.88 x 200 |
| Ask | 19.02 x 100 |
| Day's Range | 18.89 - 20.25 |
| 52 Week Range | 13.14 - 33.92 |
| Volume | |
| Avg. Volume | 312,090 |
| Market Cap | 802.22M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.00 |
Simply Wall St.Is There An Opportunity With CARGO Therapeutics, Inc.'s (NASDAQ:CRGX) 21% Undervaluation?
Key Insights CARGO Therapeutics' estimated fair value is US$25.75 based on 2 Stage Free Cash Flow to Equity Current...
GlobeNewswireCARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) –SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company’s Boar
- GlobeNewswire
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year endin
